GeneOne Life Science Inc. said its normalized net income for the third quarter amounted to 139.23 South Korean won per share, compared with a loss of 54.38 won per share in the prior-year period.
Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was 2.22 billion won, compared with a loss of 610.6 million won in the prior-year period.
The normalized profit margin climbed to 29.9% from negative 10.1% in the year-earlier period.
Total revenue rose 23.0% on an annual basis to 7.41 billion won from 6.03 billion won, and total operating expenses rose 5.3% year over year to 7.51 billion won from 7.13 billion won.
Reported net income came to 3.53 billion won, or 221.76 won per share, compared to a loss of 977.0 million won, or a loss of 87.00 won per share, in the year-earlier period.
As of Nov. 10, US$1 was equivalent to 1,159.52 South Korean won.